An Updated Review on Molecular Biomarkers in Diagnosis and Therapy of Colorectal Cancer

Overview

Journal Curr Cancer Drug Targets

Publisher Bentham Science Publishers

Specialty Oncology

Date 2023 Nov 30

PMID 38031267

Authors

Shruthi Nagainallur Ravichandran

Makalakshmi Murali Kumar

Alakesh Das

Antara Banerjee

Suhanya Veronica

Alexander Sun-Zhang

Hong Zhang

Muralidharan Anbalagan

Xiao-Feng Sun

Surajit Pathak

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer is one of the most common cancer types worldwide. Since colorectal cancer takes time to develop, its incidence and mortality can be treated effectively if it is detected in its early stages. As a result, non-invasive or invasive biomarkers play an essential role in the early diagnosis of colorectal cancer. Many experimental studies have been carried out to assess genetic, epigenetic, or protein markers in feces, serum, and tissue. It may be possible to find biomarkers that will help with the diagnosis of colorectal cancer by identifying the genes, RNAs, and/or proteins indicative of cancer growth. Recent advancements in the molecular subtypes of colorectal cancer, DNA methylation, microRNAs, long noncoding RNAs, exosomes, and their involvement in colorectal cancer have led to the discovery of novel biomarkers. In small-scale investigations, most biomarkers appear promising. However, large-scale clinical trials are required to validate their effectiveness before routine clinical implementation. Hence, this review focuses on small-scale investigations and results of big data analysis that may provide an overview of the biomarkers for the diagnosis, therapy, and prognosis of colorectal cancer.

References

Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag C, Laversanne M . Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023; 72(2):338-344. DOI: 10.1136/gutjnl-2022-327736. View

Xi Y, Xu P . Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021; 14(10):101174. PMC: 8273208. DOI: 10.1016/j.tranon.2021.101174. View

Murphy N, Moreno V, Hughes D, Vodicka L, Vodicka P, Aglago E . Lifestyle and dietary environmental factors in colorectal cancer susceptibility. Mol Aspects Med. 2019; 69:2-9. DOI: 10.1016/j.mam.2019.06.005. View

Kim C, Baek J, Choi G, Yu C, Kang S, Park W . The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous unresectable metastasis: Study protocol for a randomized controlled trial. Trials. 2016; 17:34. PMC: 4717596. DOI: 10.1186/s13063-016-1164-0. View

Pinson H, Cosyns S, Ceelen W . The impact of surgical resection of the primary tumor on the development of synchronous colorectal liver metastasis: a systematic review. Acta Chir Belg. 2018; 118(4):203-211. DOI: 10.1080/00015458.2018.1446602. View

Califf R . Biomarker definitions and their applications. Exp Biol Med (Maywood). 2018; 243(3):213-221. PMC: 5813875. DOI: 10.1177/1535370217750088. View

Chand M, Keller D, Mirnezami R, Bullock M, Bhangu A, Moran B . Novel biomarkers for patient stratification in colorectal cancer: A review of definitions, emerging concepts, and data. World J Gastrointest Oncol. 2018; 10(7):145-158. PMC: 6068858. DOI: 10.4251/wjgo.v10.i7.145. View

Wang M, Ping J, Li Y, Adell G, Arbman G, Nodin B . The prognostic factors and multiple biomarkers in young patients with colorectal cancer. Sci Rep. 2015; 5:10645. PMC: 4445043. DOI: 10.1038/srep10645. View

Zhang X, Sun X, Shen B, Zhang H . Potential Applications of DNA, RNA and Protein Biomarkers in Diagnosis, Therapy and Prognosis for Colorectal Cancer: A Study from Databases to AI-Assisted Verification. Cancers (Basel). 2019; 11(2). PMC: 6407036. DOI: 10.3390/cancers11020172. View

10.

Baylin S, Herman J . DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000; 16(4):168-74. DOI: 10.1016/s0168-9525(99)01971-x. View

11.

Imperiale T, Ransohoff D, Itzkowitz S, Turnbull B, Ross M . Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004; 351(26):2704-14. DOI: 10.1056/NEJMoa033403. View

12.

Issa J . The epigenetics of colorectal cancer. Ann N Y Acad Sci. 2000; 910:140-53; discussion 153-5. DOI: 10.1111/j.1749-6632.2000.tb06706.x. View

13.

Silva T, Vidigal V, Felipe A, de Lima J, Artigiani Neto R, Saad S . DNA methylation as an epigenetic biomarker in colorectal cancer. Oncol Lett. 2013; 6(6):1687-1692. PMC: 3834199. DOI: 10.3892/ol.2013.1606. View

14.

Sharif S, Hashemzadeh S, Ardehaie R, Eftekharsadat A, Ghojazadeh M, Mehrtash A . Detection of aberrant methylated SEPT9 and NTRK3 genes in sporadic colorectal cancer patients as a potential diagnostic biomarker. Oncol Lett. 2017; 12(6):5335-5343. PMC: 5228494. DOI: 10.3892/ol.2016.5327. View

15.

Li J, Chen C, Bi X, Zhou C, Huang T, Ni C . DNA methylation of CMTM3, SSTR2, and MDFI genes in colorectal cancer. Gene. 2017; 630:1-7. DOI: 10.1016/j.gene.2017.07.082. View

16.

Bagheri H, Mosallaei M, Bagherpour B, Khosravi S, Salehi A, Salehi R . TFPI2 and NDRG4 gene promoter methylation analysis in peripheral blood mononuclear cells are novel epigenetic noninvasive biomarkers for colorectal cancer diagnosis. J Gene Med. 2020; 22(8):e3189. DOI: 10.1002/jgm.3189. View

17.

Armstrong A, Marengo M, Oltean S, Kemeny G, Bitting R, Turnbull J . Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res. 2011; 9(8):997-1007. PMC: 3157566. DOI: 10.1158/1541-7786.MCR-10-0490. View

18.

Hao T, Shi W, Shen X, Qi J, Wu X, Wu Y . Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br J Cancer. 2014; 111(8):1482-9. PMC: 4200099. DOI: 10.1038/bjc.2014.470. View

19.

Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J . Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017; 9(403). PMC: 6714979. DOI: 10.1126/scitranslmed.aan2415. View

20.

Poulet G, Garlan F, Garrigou S, Zonta E, Benhaim L, Carrillon M . Characterization of Plasma Cell-Free DNA Integrity Using Droplet-Based Digital PCR: Toward the Development of Circulating Tumor DNA-Dedicated Assays. Front Oncol. 2021; 11:639675. PMC: 8174096. DOI: 10.3389/fonc.2021.639675. View